Antonio Martorell ha recibido honorarios y/o viajes subvenciones y/o ha actuado como miembro del consejo asesor de Novartis, Abbvie, Janssen Cilag, UCB, Lilly, LEO Pharma, LOreal, Sanofi, Boehringer Ingelheim, Almirall, Bristol Myers Squibb y Amgen
Sex-biased T-cell exhaustion drives differential immune responses in glioblastoma
Switching from another GLP-1 to semaglutide If you are transitioning from tirzepatide to semaglutide , or from another GLP-1 agonist, the dose equivalencies are not straightforward one-to-one conversions
You can basically look up a lot of different things that you use, and then they rate every single ingredient in it, and then they give it a toxicity score of 1 to 10, I think, or 1 to 8